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Humoral immunity, in particular secreted neutralizing antibodies, is of central importance to protect
the body against acutely cytopathic viruses, whereas noncytopathic viruses have found ways of bal-
anced coexistence with the immune system to avoid antibody-mediated elimination. There is evi-
dence that polyspecific ‘‘natural’’ antibodies provide early protection, independent of T cell help. If
that line of defense is crossed, T cell-dependent immune responses then generate a humoral memory
provided by long-lived plasma cells secreting specific antibodies of adapted avidity and function, i.e.,
isotype, even in the absence of virus. Secreted protective antibodies of humoral memory provide an
efficient line of defense against reinfection and are backed up by specific B and T memory cells of
reactive memory. Whereas humoral memory has developed effective antiviral protection, some
viruses (i.e., HIV) have managed to develop specific evasion strategies to escape it. Thus, coevolution
provides us with some insight into just how substantial antiviral antibodies and memory B cell are in
protecting the host from virus infection.Introduction
Viruses are intracellular pathogens and depend on living
hosts for their survival. Viruses have developed an impres-
sive array of strategies to cope with the hosts’ antiviral
defense, in particular with the immune system. Often, the
immune response against acutely cytopathic viruses (such
as neurotropic poliovirus, rabies virus, and smallpox virus
in humans) and noncytopathic viruses (such as hepatitis B
and C viruses [HBV, HCV] and herpesvirsuses, a family
that includes cytomegalo virus [CMV], herpes simplex
virus 1 and 2 [HSV-1, 2], Epstein-Barr virus [EBV], and hu-
man herpes virus 6 [HHV6]) causes more damage than the
virus itself. Acutely cytopathic viruses have to be elimi-
nated by an effective immune response or they will kill their
host. The role of the immune system in the dialog between
viruses and their host can thus be both protective and
pathogenic. With regard to the latter, a number of viruses,
e.g., CMV, EBV, varizella zoster virus (VZV), human immu-
nodeficiency virus (HIV), HBV, and HCV have developed
strategies by coevolution to avoid elimination by the
immune system that is of clinical relevance today.
Success of the immune system depends on multiple
lines of defense, addressing the pathogen at several
points of its attack. Recently, research has been directed
to barrier mechanisms and mechanisms of the innate im-
mune system. With respect to the adaptive immune sys-
tem, interest mostly focuses on cytotoxic and helper T
lymphocytes. The role of B cells and their antibodies
seems to be discussed less, although it is clear from the
early days of immunology that antibodies generated by
provocation with pathogen can protect from reiterated
challenge with pathogen, elegantly demonstrated by Kita-
sato and Behring more than 100 years ago (Behring,
1900).
How is ‘‘protective’’ humoral memory of the immune
system defined? In epidemiological terms, survival after
infection serves as the easiest outcome criterion, but its384 Immunity 27, September 2007 ª2007 Elsevier Inc.use is restricted to animal experiments with respect to in-
tentional experimental infection. There is a very limited
availability of biomarkers as ‘‘correlates of protection,’’
in particular in humans, although such biomarkers would
be very informative as to how protection is achieved. An-
tibodies specific for a pathogen and able to neutralize it in
vitro are probably one of the best correlates of protection
available so far. Although ‘‘neutralization,’’ i.e., the ability
to prevent infection of host cells by an infectious pathogen
in vitro, is a very efficient way of protection, it is probably
not the only one, and in vivo protection assays may reveal
alternative ways of protection (reviewed in Hangartner
et al., 2006).
Humoral memory, i.e., secretion of specific protective
antibodies over long periods in the apparent absence of
the antigen (Figure 1), provides the host with a first line
of defense against reinfection, defines protection against
a range of pathogens (Ahmed and Gray, 1996; Slifka and
Ahmed, 1996), and also is an informative biomarker for
previous exposure to a particular pathogen.
Pathogen-specific antibodies of the serum can be but
are not necessarily protective. It is not even clear which
proportion of serum immunglobulin (Ig) is pathogen spe-
cific and provided by the humoral memory, as compared
to ‘‘natural’’ antibodies that are preformed polyspecific
IgM antibodies not shaped by postrecombination pro-
cesses (somatic hypermutation, class switching). Be-
cause the half life of secreted antibodies is rather short,
in the range of days (Radbruch et al., 2006), their mainte-
nance over long time periods requires the persistent pres-
ence of cells secreting them. These cells, plasmablasts
and plasma cells, are generated from specific, activated
B cells, a process that can be driven by persistent antigen
(Zinkernagel and Hengartner, 2006) or that can reflect true
immunological memory. Here, we consider memory as the
maintenance of immune information in the absence of per-
sistent instruction. B cell memory is bipartite, consisting of
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ReviewFigure 1. Long-Term Antiviral Memory
Induction Induced by an Acutely
Cytopathic Virus
After vaccination or infection, B1 cells (not
shown) differentiate into plasmablasts pro-
ducing polyspecific IgM antibodies at extra-
follicular sites in a T cell-independent manner.
Simultaneously, activation of antigen-specific
CD8+ and CD4+ T cells occurs. As part of the
germinal center (GC)-reaction, CD4+ T cells
provide help to naive B cells (yellow), which
eventually become long-lived plasma cells
producing high amounts of neutralizing IgG
antibodies in the bone marrow. These naive B
cells also give rise to long-term memory B
cells. Survival niches for these cells are likely
within secondary lymphoid organs. The GC
reaction is dependent on antigen recognized
by specific B cell receptors and the presence
of specific T cells.
Survival of established long-lived plasma cells
residing in the bone marrow and memory B
cells is thought to be critically dependent on
soluble and insoluble survival factors (as indi-
cated for plasma cells in the bone marrow)
but independent of the cognate antigen and T
cell help. The hypothetical survival niche for
long-lived plasma cells is thought to comprise
adhesion molecules, cellular components,
and soluble factors, whereas the site and con-
ditions of long-lived memory B cells need to be
deciphered.long-lived antibody-secreting plasma cells (humoral
memory) and long-lived memory B cells, able to react
quickly to a recurrent antigenic challenge (reactive mem-
ory) (Ahmed and Gray, 1996). We will discuss the role of
B cell (reactive) and plasma cell (protective) memory in
the protection against acutely cytopathic viruses, a proto-
typic example of long-term protective memory (Figure 1).
B Cells Provide Several Lines of Antiviral Defense
Successful vaccination against certain viruses (measles,
chicken pox, rubella, etc.) in childhood reflects the impor-
tance of protective antibodies, and so far, vaccines in clin-
ical practice depend on the induction of neutralizing anti-
bodies but not exclusively on T cell-mediated immunity
(Zinkernagel and Hengartner, 2006). Most importantly, all
current vaccines that are clinically protective are depen-
dent on neutralizing antibody responses (Letvin, 2007, in
this issue of Immunity). Whereas cytotoxic lymphocytes
can eliminate infected cells, antibodies have the potential
to both eliminate infected cells and prevent infectious
virus from infecting a cell (neutralization).
Placental transfer of protective IgG antibodies from
mother to offspring is an impressive ‘‘demonstration by
nature’’ of the efficacy of humoral immunity. However,
agammaglobulinemic or hypogammaglobulinemic chil-
dren are less susceptible to severe viral infections than
children lacking cellular immunity. From this observation
it has often been argued that T cells are more important
than B cells in antiviral immunity. This argument neglects
the crucial importance of T helper cells not only for cellular
but also for humoral immunity, in particular the generation
of memory B cells and long-lived plasma cells. After ortho-poxvirus infection, T cells are crucial for the induction of
humoral memory in primary responses (Figure 1) and
become of secondary importance in secondary respon-
ses, when neutralizing antibodies play an important role
in protection against reinfection (Edghill-Smith et al.,
2005).
A number of studies compared the induction and main-
tenance of specific T and B cell responses and resulting
antiviral titers. In this regard, it was shown that antiviral an-
tibody can protect mice efficiently, even if CD4+ or CD8+ T
cells have been depleted prior to viral (re)challenge (Belya-
kov et al., 2003; Xu et al., 2004). Humans make strong
CD8+ and CD4+ T cell immune responses after receiving
smallpox vaccine (Edghill-Smith et al., 2005; Hammarlund
et al., 2003). Quantitative studies (Figure 2) examining the
magnitude and duration of vaccinia-specific T cell re-
sponses found that effector CD8+ T cell responses peak
at approximately 2 (Amara et al., 2004; Terajima et al.,
2003) to 5 weeks after vaccination (Amara et al., 2004;
Hammarlund et al., 2003; Rock et al., 2005). Interestingly,
a decline of circulating vaccinia-specific CD8+ T cells
(Amara et al., 2004; Hammarlund et al., 2003; Terajima
et al., 2003) and specific CD4+ T cells (Amara et al.,
2004) was noted. Antivaccine Ig was more stable than
CD8+ and CD4+ T cells (Hammarlund et al., 2003). In this
context, a cross-sectional analysis (Hammarlund et al.,
2003) of 306 individuals who received smallpox vaccine
demonstrated that vaccinia virus-specific memory CD4+
T cells were long lived with an overall half-life time of
8–12 years (Amara et al., 2004; Crotty et al., 2003).
Vaccinia-specific memory CD8+ T cells were also long
lived, but only half of the vaccinees had detetableImmunity 27, September 2007 ª2007 Elsevier Inc. 385
Immunity
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Defense against an Acutely Cytopathic
Virus
At early stages of infection with an acutely
cytopathic virus such as vaccinia (viral load
in red line), specific CD4+ and CD8+ T cells
are expanded. Polyreactive antiviral IgM anti-
bodies are likely induced as a first defense
that lacks clear identification in antiviral re-
sponses. As a result of successful GC reac-
tions, long-lived plasma cells are induced,
providing neutralizing antibodies. The half-life of long-lived plasma cells has been reported to be longer than that of CD4+ or CD8+ T cells, although
tested by only a limited number of studies. It has been argued that there is no intrinsic half-life of long-lived plasma cells, but rather that their survival
is conditional on being in a survival niche (Radbruch et al., 2006). The vertical dotted line indicates the assumed lower level of detection.vaccine-specific memory CD8+ T cells 20 years after vac-
cination. The longevity of B cell and CD4+ and CD8+ T cell
memory and antiviral antibody responses observed in
available human studies appears to be different and likely
reflects the complex and different regulation of these
memory compartments. How their induction and mainte-
nance are managed and whether different vaccinations
or viral infections lead to differences in their halflives
remain to be elucidated.
The characteristic of long-standing antiviral antibodies
to be dependent on previous T cell instruction has been
analyzed by a number of studies. Mice infected with a cy-
topathic virus, which cannot persist in the host, e.g., inac-
tivated vesicular stomatitis virus (VSV) Indiana, develop
very high titers of neutralizing antibodies rapidly (Ochsen-
bein et al., 2000). By day 300 after infection, however,
antibody titers decline below detectable amounts for
neutralizing antibodies. These antibodies are likely thus
secreted by short-lived plasma cells. Titers of non-
neutralizing antibodies against the virus remain high be-
yond day 300. They are either derived from long-lived
plasma cells or from short-lived plasma cells generated
continously in a chronic immune reaction driven by persis-
tent antigen. Thus a primary immune response against an
acutely cytopathic virus, which is eliminated rather quickly
and before the specific memory T and B cells can be reac-
tivated by virus, is apparently not sufficient to generate
humoral memory of protective antibodies. In transfer ex-
periments, stable titers of neutralizing antibodies in naive
recipients developed only after transfer of primed T and
B cells plus antigen and not without antigen (Ochsenbein
et al., 2000), in line with the concept that long-lived plasma
cells can be generated only from memory B cells (Ochsen-
bein et al., 2000; reviewed in Radbruch et al., 2006), either
by reinfection with acutely cytopathic viruses, like VSV, or
in the prolonged initial immune response to replicating,
persistent virus, like LCMV, allowing reactivation of mem-
ory B cells (Bachmann et al., 2004). Such secondary acti-
vations in initial immune responses have been described
and analyzed in detail in mice immunized with 4-hydroxy-
3-nitrophenyl)acetyl-KLH (NP-KLH) (Blink et al., 2005).
A drastic example of the maintenance of stable titers
of neutralizing antibodies in the absence of pathogen is
provided by poxvirus vaccination. Antibody responses
after secondary vaccination are detected as early as day
4 after immunization (Amanna et al., 2006). Peak antibody386 Immunity 27, September 2007 ª2007 Elsevier Inc.responses decline during the first year after vaccination,
but antibody titers then stabilize and remain nearly con-
stant for up to 75 years after immunization (Hammarlund
et al., 2003; Crotty and Ahmed, 2004; Slifka, 2004).
In humans, application of vaccinia immunoglobulin re-
duces the spreading of smallpox virus infection, when ad-
ministered simulataneously with the vaccine to contacts
(Amanna et al., 2006), and also reduces disease severity
(Peirce et al., 1958). High neutralizing antibody titers are
associated with protective immunity against acutely cyto-
pathic smallpox infection, although there is no simple cor-
relation between stable antibody titers and T cell memory
(Crotty et al., 2003; Hammarlund et al., 2005). This argues
against the idea that high antibody titers recognizing gly-
coprotein structures are simply reflecting pre-existing T
cell memory with reactivity against peptide structures be-
cause of their distinct biochemical receptor recognition
pattern. Rather, the competence to generate long-lived
plasma cell memory might depend on the availability of
precursor memory B cells.
Apart from humoral memory, the humoral immune sys-
tem also provides a first line of defense against initial viral
infection, namely the polyspecific (‘‘natural’’) antibodies
secreted by plasma cells derived from B1 B cells (Haury
et al., 1997; Baumgarth et al., 1999). These antibodies
are considered a link between innate and adaptive immu-
nity. They limit dissemination of the pathogen, form im-
mune complexes for activating the adaptive immune reac-
tion, recruit antigen into germinal centers, and activate
complement. The antiviral repertoire of ‘‘natural anti-
bodies’’ seems to be far from complete, and apparently
they are not as efficient protectors as antibodies of hu-
moral memory, which provide additional effector functions
by switched isotype, i.e., constant region of the heavy
chain, and improved affinity. The increase in affinity may
be critical in maintaining avidity for the pathogen in the
switch from decavalent IgM to bivalent IgG, IgE, or IgA.
It is remarkable that plasma cells secreting ‘‘natural’’ an-
tibodies are rarely recruited into the pool of long-lived
plasma cells. It has been argued that most of those anti-
bodies probably are also autoreactive (Haynes et al.,
2005) and thus are eliminated from memory by tolerance
mechanisms yet to be defined. In this context, two human
mAb with anti-HIV neutralizing capacity 2F5 and 4E10
have been reported that also showed reactivity against
the autoantigen cardiolipin (Haynes et al., 2005). If not
Immunity 27, September 2007 ª2007 Elsevier Inc. 387
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bodies oligo- or monospecific. In humoral protection
against highly variable viruses, these antibodies may
play a crucial role. Rare long-term nonprogressing HIV-
infected persons (Deeks and Walker, 2007, in this issue
of Immunity) have been described who are apparently
also protected by their polyspecific antibodies, covering
a wide range of HIV genotypes (Mascola and Montefiori,
2003; Braibant et al., 2006). Indeed, in view of our current
concept of the stability of plasma cell memory (see below),
HIV has managed to circumvent targeting by oligospecific
antibodies by mutation as well as targeting by polyspecific
antibodies. In addition, the lack of CD4+ T cell help results
in a substantial reduction of memory B cells, limiting
reactive memory.
In antiviral defense, B cells play a central role by provi-
ding protective ‘‘natural’’ antibodies in the first line, hu-
moral memory antibodies in the second line, and reactive
memory B cells in the third line of protection.
Humoral Memory Establishment Is Dependent
on T Cell Help
In systemic T cell-dependent immune responses to pro-
tein antigens and viruses, the early antibody response is
provided by short-lived plasmablasts and plasma cells,
whereas later on the humoral response is primarily pro-
vided by long-lived plasma cells, with specific memory B
cells maintained as backup system (Odendahl et al.,
2005). Recruitment of plasma cells generated late in the
immune reaction to the pool of long-lived plasma cells
ensures that the memory plasma cells secrete antibodies
of the highest affinity (Blink et al., 2005). After acute viral
infection, the virus-specific antibody-secreting cells of
bone marrow differ from those in the spleen in terms of
increased virus-specific ELISPOT formation, suggesting
that affinity maturation and selection occurs before plasma
cells accumulate in the bone marrow or when plasma-
blasts develop into plasma cells (Slifka and Ahmed, 1996).
Convincing evidence supporting the hypothesis that
selection occurs before plasma cell migration and/or ac-
cumulation in the bone marrow has been provided by
characterization of affinity maturation in the spleen and
bone-marrow compartments after a primary antibody re-
sponse (Smith et al., 1997).
The precise mechanisms governing the recruitment of
plasma cells to the memory plasma cell compartment
are still not clear. As discussed in detail elsewhere (Ho¨fer
et al., 2006; Manz et al., 2005; Radbruch et al., 2006), long-
lived plasma cells depend on a dedicated environment
for their survival, the ‘‘plasma cell survival niche.’’ Such
niches are found predominantly in the bone marrow and
to a lesser extent in secondary lymphoid organs, like the
spleen, and in inflamed tissue. Whereas plasmablasts
are migratory for about 1 week after their generation,
plasma cells are not. Plasmablasts from systemic immune
responses are attracted by the chemokine CXCL12 (SDF-
1a), the ligand of CXCR4, and are dependent on instruc-
tion by IFN-g and by CXCL9, 10, and 11, the ligands of
CXCR3. Interestingly, although long-lived plasma cellsare no longer migratory, their survival is supported by
CXCL12, i.e., plasmablasts are attracted to and can
migrate toward survival niches for long-lived plasma cells.
We have postulated and provided indirect evidence for
competition between newly generated plasmablasts and
established resident long-lived plasma cells for habitation
of a limited number of survival niches (Odendahl et al.,
2005). Such a mechanism would combine a remarkable
stability of established humoral memory responses with
an efficient recruitment of new specificities to memory
(Ho¨fer et al., 2006), because for each newly recruited
plasmablast, only one ‘‘old’’ plasma cell would be elimi-
nated. At an estimated repertoire size of 1,000 to 10,000
specificities of humoral memory, this would imply the
elimination of 0.1% to 0.01% of ‘‘old’’ plasma cells of
each specificity to adapt one new specificity to the pool.
It should be noted that the ability to compete with long-
lived plasma cells for survival niches seems to be depen-
dent on as-yet-undefined molecular competence of plas-
mablasts and that long- and short-lived plasma cells can
coexist even in the same organ (Hoyer et al., 2004).
Efficient generation of long-lived plasma cells so far has
been observed mostly in secondary systemic T cell-
dependent immune reactions.
Vaccinia virus infection and immunization is one of the
classical examples of generation of long-term immunity
against viral reinfection. The kinetics of the specific im-
mune responses vary quantitatively and qualitatively for
the various hosts analyzed, depending on the hosts’ im-
munocompetence, the route of adminstration of antigen,
adjuvants used, dose of antigen, and previous immuniza-
tions of the host (Earl et al., 2004), according to rules not
defined so far.
In vaccinia virus-specific responses, the kinetics and
duration of T cell responses (Harrington et al., 2002)
showed strong CD8+ T cell responses (about 30% of all
CD8+ T cells) at day 7 postinfection in mice, which then
declined over time and stabilized by day 30 for up to
300 days after infection. In monkeys immunized with an
attenuated modified vaccinia virus Ankara vaccine,
a strong CD8+ T cell response peaked at approximately
2 weeks after immunization (Earl et al., 2004) at a fre-
quency of 0.1% and 1% specific cells of CD8+ T cells.
Vaccinia-specific CD4+ T cell responses in mice also
peak at approximately 1 week after infection, with 4%–
5% of total splenic CD4+ T cells (Harrington et al., 2002;
Xu et al., 2004), and reach a plateau 1 to 7 months after
infection (Harrington et al., 2002).
Vaccinia-specific memory B cells can make up up to
1% of circulating IgG+ memory B cells 1–6 months after
vaccination (Crotty et al., 2003). The number of vaccine-
specific B cells declines by about 90% during the first
year after vaccination and then stabilizes, with vaccinia-
specific IgG+ memory B cells being maintained for more
than 50 years (Crotty et al., 2003). The kinetics of gener-
ation of vaccinia-specific serum antibodies has mainly
been analyzed in mice (Tscharke et al., 2002; Wyatt
et al., 2004). Antibody responses after vaccinia virus in-
fection were detectable at low amounts at day 7 after
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day 14 (Spriggs et al., 1992). Antibody titers reached a pla-
teau 1 month after infection (Xu et al., 2004). Interestingly,
these antivaccinia responses were almost completely
CD4+ T cell dependent, initially with a minor T cell-
independent IgM component (Xu et al., 2004). Dissecting
the relative contributions of CD8+ and CD4+ T cells and
B cells by genetic or serological depletion has clarifyed
the relative contributions of cellular and humoral immune
components in immunity to vaccinia virus in mice. Transfer
of serum or primed CD8+ T cells both was protective, but
CD4+ T cell-dependent antiviral antibodies clearly played
a more important role in clearing the virus than CD8+ T
cell-mediated protection, as was evident from the differ-
ential inactivation (Xu et al., 2004). Humans make antibody
responses to several vaccinia virus proteins after immu-
nization (Demkowicz et al., 1992; Davies et al., 2005a;
Jones-Trower et al., 2005) with distinct immunodominant
targets, like H3L, which have been shown to be protective
in mice (Davies et al., 2005b). The H3L protein is a viral re-
ceptor involved in cell adhesion, and it is highly conserved
among the orthopoxviruses. There is a correlation be-
tween pre-existing serum-neutralizing antibody titers and
protection against smallpox (Mack et al., 1972). In case of
vaccinia, H3L has been identified as the first target of neu-
tralizing antibodies against a smallpox vaccine (Dryvax)
(Davies et al., 2005b). Thus, protection and conservation
are probably closely related in that long-term protection
by antibodies secreted by long-lived plasma cells, which
can no longer change the affinity of their antibodies, is
most efficient if the target antigen cannot be modified by
the virus.
Rapid anamnestic antibody responses after infection
appear to be primarily driven by the size of the reactive
memory B cell compartment and the quality of its anti-
bodies. Individuals with an enlarged frequency of memory
B cells specific for major antigenic targets would be ex-
pected to be more efficiently protected than individuals
with a memory B cell pool dominated by specificities for
nonprotective antigens. With regard to the T (memory)
cells, the role of CD40/40L and ICOS/ICOS-L and cyto-
kines regulating plasmablast differentiation, Ig class
switching, and affinity maturation are relevant (Durandy
et al., 2004).
So far, generation of long-lived plasma cells has been
observed only in T cell-dependent immune reactions.
Whether this reflects the requirement of a particular costi-
mulatory signal making plasmablasts competent for lon-
gevity or whether such competent plasmablasts can be
generated only from memory B cells, which in turn require
T cell help for their generation, is currently not clear (Rad-
bruch et al., 2006). By definition, induction of T-dependent
(TD) humoral immune responses requires CD4+ T cell help,
although the precise molecular nature of this help may
vary (Cobbold et al., 1984; Coulie et al., 1985; Wofsy
et al., 1985). CD4+ T cells appear to play different roles de-
pending on the antigen and the phase of the immune re-
sponse during induction, maintenance, and reactivation
after secondary challenge.388 Immunity 27, September 2007 ª2007 Elsevier Inc.CD4+ T cell depletion studies have shown that the in-
duction of strong antibody responses requires an intact
CD4+ T cell compartment (Vieira and Rajewsky, 1990). Al-
though a very early stage of immune reaction seems to be
T cell independent (Blink et al., 2005; Hangartner et al.,
2006; Haury et al., 1997; Baumgarth et al., 1999), subse-
quent CD4+ T cell help is strictly dependent on CD40L
costimulation (Banchereau et al., 1994; Whitmire et al.,
1996) and may also involve other CD28 family members,
such as ICOS/ICOS-L (Lo¨hning et al., 2003). The induction
phase is rather short, and the later T cells are depleted af-
ter immunization in experimental setups, the less it mat-
ters for the magnitude of the humoral response, indicating
the dispensability for CD4+ T cell help after the induction
phase (Coulie et al., 1985; Vieira and Rajewsky, 1990;
Wofsy et al., 1985). If CD4+ T cell depletion is delayed until
approximately 3 weeks after immunization, then antigen-
specific antibody responses are no longer affected (Vieira
and Rajewsky, 1990).
The critical role of CD4+ T cell help for the establishment
of B and plasma cell memory is also evident from patients
with HIV infection. In these patients with aquired immuno-
deficiency syndrome, i.e., impairment of the CD4+ T helper
cell compartment, immune responses to other viruses can
be compromised. In this regard, AIDS patients with CD4+
T cell counts below 50 cells/mm3, when immunized with
a recombinant strain of vaccinia virus, were reported
with fatal viral complications (Zagury, 1991), consistent
with a report on vaccination with replication-competent
vaccinia virus (Bartlett, 2003) that resulted in life-threaten-
ing infection of a patient with CD4+ T cell counts below
25 cells/mm3.
In summary, interaction of antigen-specific T and B lym-
phocytes is required to generate humoral antiviral memory
upon prolonged or repeated challenge with a viral patho-
gen. This memory is provided by long-lived plasma cells
and is independent of B and T memory cells, once it is
established.
Persistence of Humoral Immunity
Major advances have been made in identifying antigen-
independent mechanisms of maintaining immunological
memory (Becker et al., 2002; Blattman et al., 2002; Freitas
and Rocha, 2000; Lanzavecchia and Sallusto, 2002). First
of all, maintenance of B cell memory and long-term anti-
body production can occur in the absence of continued
CD4+ T cell help (Vieira and Rajewsky, 1990). CD4+ T cells
were continuously depleted for up to 6 weeks without any
substantial effect on B cell memory (Vieira and Rajewsky,
1990). Memory B cells, when adoptively transferred into
T cell-deficient hosts, survive for at least 90 days in the
absence of a detectable CD4+ T cell population (Hebeis
et al., 2004).
Memory CD4+ T cells and memory CD8+ T cells can per-
sist in the absence of antigen (reviewed in Amanna et al.,
2006). Murine memory CD8+ T cells undergo homeostatic
proliferation, and this is independent of antigen or MHC I-
dependent antigen presentation (Kassiotis et al., 2002;
Murali-Krishna et al., 1999; Sprent and Surh, 2002, 2003;
Immunity
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CD8+ T cells are stably maintained, whereas CD4+ mem-
ory T cell numbers appear to decline slowly (Homann
et al., 2001).
There is no statistical correlation between CD4+ T cell
memory and long-term serum antibody titers against vac-
cinia (Crotty and Ahmed, 2004; Hammarlund et al., 2003),
in line with the concept that CD4+ T cell help is not required
for the maintenance of this specific humoral memory.
Maintenance of humoral memory in face of HIV-induced
depletion of T cell help has also been studied in AIDS pa-
tients. Pre-existing antibody titers to a variety of patho-
gens do not change in these patients (Naniche et al.,
2004). A lack of quantitative correlation between T cell
memory and humoral memory has also been described
for memory to measles virus, after natural infection or vac-
cination 23 to 47 years after exposure to the virus or 1–34
years after vaccination (Naniche et al., 2004). A substantial
decrease in CD4+ T cell memory at time points more than
21 years after vaccination was observed, but a similar
decrease was not seen in measle virus-specific antibody
titers.
If neither T cells nor antigen maintain memory B and
long-lived plasma cells, what does? Concepts regarding
the mechanisms underlying the persistence of specific an-
tibody production have focused primarily on the memory
B cell component of humoral immunity (Schittek and
Rajewsky, 1992; Gray et al., 1996; Lam et al., 1997; Mar-
uyama et al., 2000) and plasma cell longevity (Manz
et al., 1997; Slifka et al., 1998).
For long-lived plasma cells, it is still discussed whether
they may have an intrinsic half-life or whether their sur-
vival is conditional on the specialized environment of the
‘‘plasma cell survival niche’’ (reviewed in Radbruch
et al., 2006). For memory B cells, it remains controversial
whether or not they undergo homeostatic proliferation
and how this might be regulated (Schittek and Rajewsky,
1992). From in vivo labeling with heavy glucose (Makela
and Nossal, 1962) or analysis of expression of the prolifer-
ation marker Ki67 (Gray et al., 1996), it has been con-
cluded that approximately 2% of human memory B cells
divide every day. This may or may not be driven by their
antigen receptor (Lam et al., 1997), similar to T cells (Mur-
ali-Krishna et al., 1999). Independent of antigen receptor,
human memory B cells could be maintained through acti-
vation via pathogen-associated molecular pattern recep-
tors, e.g., toll-like receptors (TLRs), and cytokine recep-
tors, although Bernasconi and collegues have shown
that memory B cells, when bystander activated in vitro
with TLRs ligands and/or cytokines, differentiate exclu-
sively into plasmablasts (Bernasconi et al., 2002) and not
also into memory B cells. Programmed homeostatic pro-
liferation has been suggested to maintain human memory
B cells, perhaps by a depot of antigen (Ochsenbein et al.,
2000; Haberman and Shlomchik, 2003; Mandel et al.,
1980), although it has been shown recently that secreted
antibody, i.e., immune complexes and antigen on follicular
dendritic cells, are not required to maintain B cell memory
(Anderson et al., 2006). Persistent antigen may play a rolein chronic immune reactions, with persistent antigen
perpetuating memory B cells, and at the same time gen-
erating plasmablasts. In this context, preplasma cells
proliferating and differentiating have been described
(Kelsoe, 1996; Miller, 1964), as well as steady-state, low-
frequency, peripheral antibody-secreting cells (Slifka and
Ahmed, 1998). However, the continous generation of
virus-specific plasma cells is difficult to explain for acutely
cytopathic viruses, such as smallpox (Hammarlund et al.,
2003) with no clinically apparent retention of the virus and
a decline of CD4+ and CD8+ T cell memory over time
(Hammarlund et al., 2003).
Long-lived plasma cells have been shown to survive in-
dependent of antigen (Manz et al., 1998; Slifka et al.,
1998). Instead, they require distinct signals from their en-
vironment, the plasma cell survival niche (Cassese et al.,
2003). Although the molecular code of the ‘‘plasma cell
survival niche’’ is not deciphered so far, signals such as
CXCL12, IL6, B cell-activating factor (BAFF), apoptosis-
inducing ligand (APRIL), and CD44 are most likely in-
volved, although not essential. Genetic blocking of the re-
spective signaling pathways has in no instance eliminated
the pool of long-lived plasma cells. Whereas the interac-
tion of CXCR4 and CXCL12 is important for the recruit-
ment of newly generated competent migratory and com-
petent plasmablasts to the pool of long-lived plasma
cells, the ligation of FcgRIIb (CD32) with immune complex
and subsequent signaling has been discussed with re-
spect to elimination of plasma cells from the this pool
(Xiang et al., 2007). It should, however, be noted that so
far it has not been shown that long-lived plasma cells
can be killed by immune complexes in their survival
niches.
Taken together, T cell, B cell, and plasma cell memories
against viruses are apparently differentially regulated and
can be maintained independent of each other. The distinct
instructions and conditions of survival of these memory
cells are of utmost interest.
Viral Evasion and Deception Strategies
There are increasing numbers of reports on viral evasion
strategies (reviewed by Hangartner et al., 2006; Gruen-
berg and van der Goot, 2006; Mohamadzadeh et al.,
2006). Viruses can deteriorate T-B cell and T-DC interac-
tion within secondary lymphoid organs and impair their ar-
chitecture. In this context, filovirus glycoproteins can bind
to receptors of immune cells and interfere with their func-
tion as well as mask important antigenic sites (Mohamad-
zadeh et al., 2006). Another example of interference with B
cell reactivity is direct binding of HIV-1 to CD21, the com-
plement receptor 2 on B cells (Moir et al., 2000) promoting
virus dissemination to T cells. For HSV and CMV, it
has been shown that CD1 antigen presentation by DCs
is a target of evasion (Raftery et al., 2006).
With regard to humoral memory, viruses have devel-
oped escape and deception strategies to escape natural
antibodies, by infecting unprotected individuals and
changing their antigenicity (serotypes or subtypes). A typ-
ical example is influenza A virus, which mutates antigenicImmunity 27, September 2007 ª2007 Elsevier Inc. 389
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also includes modifications of O- and N-glycosylation
and glycoprotein shedding of filoviruses (Mohamadzadeh
et al., 2006) supporting the relevance of glycoprotein
structures for recognition of antigens by B and T cell
receptors. Continous mutation of the target epitopes to
escape neutralizing antiviral antibodies is an immune eva-
sion mechanism used by HIV. Sera from infected patients
were unable to neutralize HIV from the same donor but
could readily neutralize isolates obtained months ago
(Richman et al., 2003; Wei et al., 2003). This indicates
that HIV immune evasion is due to (1) escape of virus from
the specificity of initially generated humoral memory and
(2) the inability of the immune system to create protective
humoral memory for the mutated virus, probably by im-
pairment of T cell help. It has been hypothesized that the
unique ability of B cells to vary their antigen receptors by
somatic hypermutation may enable the human host to
compete with the viral mutation rates (Hangartner et al.,
2006), but by escape from protective memory and subver-
sion of reactive memory, HIV may have found a way to win
the race.
More successful in evolutionary terms are probably
nonacutely cytopathic viruses, which have found numer-
ous ways to coexist with their human hosts, thereby avoid-
ing the generation of efficient protective humoral memory
in the first place.
Conclusions
The humoral immune system of vertebrates plays an es-
sential role in their protection against acutely cytopathic
viruses. The two compartments of memory B cells and
long-lived plasma cells provide separate lines of humoral
immunity. Long-lived plasma cells secrete protective anti-
bodies of high specificity and adapted function. Memory B
cells provide the potential to react fast and with even more
adapted antibodies against reinfection. Induction of long-
term plasma cells and memory B cells apparently is de-
pendent on CD4+ T cell help and B cell receptor signaling.
Their maintenance appears to be independent of viral an-
tigen. Viral evasion and deception strategies reflect the
essential role of protective long-lived plasma cells and re-
active memory B cells in antiviral defense. Understanding
the rules governing the differential generation of memory
B cells versus long-lived plasma cells from the same
precursors, and the mechanisms maintaining them, will
provide exciting new options to develop novel, efficient
antiviral vaccines.
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